Iso-A11B5C1
Instructions for Use
Product information
Iso-A11B5C1 is an asymmetric Ugi-reaction-derived ionizable lipid selected for muscle-focused mRNA delivery. In the cited mouse study, its optimized LNP produced muscle expression comparable to an SM-102 benchmark after intramuscular administration while showing no measurable reporter expression in the examined off-target organs. The same formulation delivered Cre mRNA for localized muscle gene editing and was evaluated with model-antigen and cancer-vaccine mRNAs. All formulation and performance information shown below is literature-derived study evidence, not a product specification or a guarantee of reproducible LNP performance.
| CAS No. | Not available |
| Chemical Name | Iso-A11B5C1 |
| Formula | C41H79N3O3 |
| M.Wt | 662.10 |
| Purity | ELSD-HPLC>95% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
Formulation & study context
Literature information refers to the cited study and its particular formulation. Administration routes are research context, not clinical instructions or a guarantee of performance.
| Component | mol% | Role |
|---|---|---|
| Iso-A11B5C1 | 60 | Ionizable lipid |
| DOPE | 10 | Helper phospholipid |
| Cholesterol | 29 | Sterol |
| C14-PEG2000 (14:0 PEG2000 PE) | 1 | PEG lipid |
| Reported total | 100 | Source values retained |
| N/P ratio | Not reported in the cited article |
| Total lipid:cargo weight ratio | 10:1 ionizable lipid:mRNA (w/w); this is not an N/P ratio |
| Buffer & pH | Aqueous phase pH 4.5 in the optimized DOE formulation; buffer identity is not stated in the main article |
| Cargo | Firefly luciferase mRNA (mLuc) |
| Administration route | Intramuscular injection |
| Dose | 0.3 mg mRNA/kg, single dose |
| Animal model | C57BL/6 mice |
| Formulation process | The optimized composition was selected by a six-factor DOE. In vivo formulations used 3:1 v/v aqueous:ethanol phases and T-junction mixing, followed by 12 h dialysis against 1× PBS at 4 degrees C with a 10 kDa membrane. Total flow and final mRNA concentration are not reported. |
N/P is the molar ratio of specified lipid nitrogen groups to nucleic-acid phosphate groups. A lipid:cargo mass ratio is a different quantity and must not be used as N/P.
Stock-solution preparation table
Calculated from the product-page molecular weight: 662.1 g/mol. Volumes are final solution volumes.
| Lipid mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | 15.103 mL | 3.021 mL | 1.510 mL |
| 25 mg | 37.759 mL | 7.552 mL | 3.776 mL |
| 50 mg | 75.517 mL | 15.103 mL | 7.552 mL |
| 100 mg | 151.035 mL | 30.207 mL | 15.103 mL |
| 250 mg | 377.586 mL | 75.517 mL | 37.759 mL |
Volume (mL) = mass (mg) × 1000 / [MW (g/mol) × concentration (mM)]. These are mathematical conversions, not measured solubility or validated solvent recommendations. Confirm solvent compatibility and the molecular weight of the exact material before use.
Open editable solution calculators →Handling & storage
Provided that storage conditions are as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 1 year.
Wherever possible, prepare and use solutions on the same day. If stock solutions must be prepared in advance, store them as aliquots in tightly sealed vials at -20°C. Generally, these will be usable for up to one month.
Before use, and prior to opening the vial, allow the product to equilibrate to room temperature for at least 1 hour.
References
Cited literature for this formulation and performance dataset Chen J, Xu Y, Zhou M, et al. Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects. Proceedings of the National Academy of Sciences of the United States of America. 2023;120(50):e2309472120. DOI: 10.1073/pnas.2309472120 Structure and synthesis: main Figure 1F and Supporting Information pp. 19-20; DOE composition: main Figure 2 and text p. 4 plus Supplementary Table S2; pKa and muscle-selective delivery: main Figures 2-3; vaccine and melanoma studies: main Figures 4-5.